ObsEva SA Link to Annual Report 2019
05 mars 2020 04h43 HE
|
ObsEva SA
Geneva, Switzerland and Boston, MA – March 5, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
ObsEva Announces Year End 2019 Financial Results and Business Update
05 mars 2020 01h00 HE
|
ObsEva SA
Primary endpoint achieved in 94% of women in linzagolix Phase 3 PRIMROSE 2 trial in uterine fibroids Linzagolix Phase 3 PRIMROSE 1 six-month primary endpoint results and PRIMROSE 2 twelve-month...
Correction: ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020
18 févr. 2020 03h48 HE
|
ObsEva SA
Geneva, Switzerland and Boston, MA – February 18, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020
18 févr. 2020 01h00 HE
|
ObsEva SA
Geneva, Switzerland and Boston, MA – February 18, 2019 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco
15 janv. 2020 01h00 HE
|
ObsEva SA
Phase 3 linzagolix trials expected to generate additional data in uterine fibroids in Q2:20 with first linzagolix regulatory filing planned for late 2020Enrollment of linzagolix US and EU Phase 3...
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
09 déc. 2019 01h00 HE
|
ObsEva SA
Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints93.9% responder rate for 200 mg with ABT (p < 0.001)56.7% responder rate for 100 mg without ABT (p < 0.001)Both doses...
ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019
06 déc. 2019 16h30 HE
|
ObsEva SA
Geneva, Switzerland and Boston, MA –December 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
11 oct. 2019 01h00 HE
|
ObsEva SA
Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of endometriosis-association pain and heavy bleeding from uterine fibroids while...
ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA
09 oct. 2019 01h00 HE
|
ObsEva SA
Geneva, Switzerland and Boston, MA –October 9, 2019- ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of...
ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
08 juil. 2019 01h00 HE
|
ObsEva SA
Geneva, Switzerland and Boston, MA – July 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...